4-[(2-methyl-4-quinolinyl)methoxy]benzyl chloride | 676606-88-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-[(2-methyl-4-quinolinyl)methoxy]benzyl chloride
• 英文别名: 4-[[4-(chloromethyl)phenoxy]methyl]-2-methylquinoline
• CAS: 676606-88-5
• 化学式: C₁₈H₁₆ClNO
• 分子量: 297.784
• InChiKey: OMLYLEFJTFKDGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-[(2-methyl-4-quinolinyl)methoxy]benzyl chloride 、 N-Boc-4-羟基哌啶 在 NaH 、 三氟乙酸 作用下， 以 四氢呋喃 、 正己烷 、 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 、 乙酸乙酯 为溶剂， 生成 2-Methyl-4-(piperidin-4-yloxymethyl)-quinoline
  参考文献：
  名称：

  Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)

  摘要：

  本申请描述了式（I）的新颖咪唑烷二酮衍生物：1或其药用盐或前药形式，其中L、Z0、R1、R4、R5和R11如本规范中定义，这些衍生物可作为基质金属蛋白酶（MMP）、TNF-α转化酶（TACE）、聚集素酶的抑制剂，或者两者的组合。

  公开号：

  US20040067996A1
• 作为产物：
  描述：

  4-氯-3-甲酚 、 4-氯甲基-2-甲基喹啉 在 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 以81%的产率得到4-[(2-methyl-4-quinolinyl)methoxy]benzyl chloride
  参考文献：
  名称：

  Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-α converting enzyme

  摘要：

  New inhibitors of tumor necrosis factor-a converting enzyme (TACE) were discovered with a pyrimidine-2,4,6-trione in place of the commonly used hydroxamic acid. These non-hydroxamate TACE inhibitors were developed by incorporating a 4-(2methyl-4-quinolinylmethoxy)phenyl group, an optimized TACE selective P1' group. Several leads were identified with IC50 values around 100 nM in a porcine TACE assay and selective over MMP-1, -2, -9, -13, and aggrecanase. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.039

文献信息

• Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
  申请人：Bristol-Myers Squibb Company

  公开号：US07041693B2

  公开（公告）日：2006-05-09

  The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein L, Z0, R1, R4, R5, and R11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof.

  本申请描述了式(I)的新型脲嘧啶衍生物，或其药学上可接受的盐或前药形式，其中L、Z0、R1、R4、R5和R11在本说明书中有定义，它们可用作基质金属蛋白酶(MMP)、TNF-α转化酶(TACE)、聚集素酶或其组合的抑制剂。
• HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME (TACE)
  申请人：Bristol-Myers Squibb Company

  公开号：EP1546109A2

  公开（公告）日：2005-06-29
• EP1546109A4
  申请人：——

  公开号：EP1546109A4

  公开（公告）日：2005-11-09
• US7041693B2
  申请人：——

  公开号：US7041693B2

  公开（公告）日：2006-05-09
• [EN] HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME (TACE)<br/>[FR] DERIVES D'HYDANTOINE EN TANT QU'INHIBITEURS DE METALLOPROTEINASES MATRICIELLES ET/OU DE L'ENZYME DE CONVERSION DE TNF-ALPHA (TACE)
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2004033632A2

  公开（公告）日：2004-04-22

  The present application describes novel hydantoin derivatives of formula (I) or pharmaceutically acceptable salt or prodrug forms thereof, wherein L, Z0, R1, R4, R5, and R11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-a converting enzyme (TACE), aggrecanase, or a combination thereof.